CERE
Price:
$44.96
Market Cap:
$8.19B
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a sel...[Read more]
Industry
Biotechnology
IPO Date
2020-07-30
Stock Exchange
NASDAQ
Ticker
CERE
According to Cerevel Therapeutics Holdings, Inc.’s latest financial reports and current stock price. The company's current ROE is -98.94%. This represents a change of 270.69% compared to the average of -26.69% of the last 4 quarters.
The mean historical ROE of Cerevel Therapeutics Holdings, Inc. over the last ten years is -129.47%. The current -98.94% ROE has changed -23.58% with respect to the historical average. Over the past ten years (40 quarters), CERE's ROE was at its highest in in the September 2020 quarter at 5.23%. The ROE was at its lowest in in the June 2020 quarter at -622.63%.
Average
-129.47%
Median
-65.84%
Minimum
-668.31%
Maximum
0%
Discovering the peaks and valleys of Cerevel Therapeutics Holdings, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 529.29%
Maximum Annual ROE = 0%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -668.31%
Year | ROE | Change |
---|---|---|
2023 | -64.24% | -4.74% |
2022 | -67.44% | 75.45% |
2021 | -38.44% | -2.86% |
2020 | -39.57% | -76.02% |
2019 | -164.98% | -Infinity% |
2018 | 0% | -100.00% |
2015 | -668.31% | 529.29% |
2014 | -106.20% | 7.82% |
2013 | -98.50% | 109.53% |
2012 | -47.01% | -Infinity% |
The current ROE of Cerevel Therapeutics Holdings, Inc. (CERE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-56.71%
5-year avg
-74.93%
10-year avg
-129.47%
Cerevel Therapeutics Holdings, Inc.’s ROE is greater than Avidity Biosciences, Inc. (-32.89%), greater than Revolution Medicines, Inc. (-34.57%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than SpringWorks Therapeutics, Inc. (-56.13%), greater than Ventyx Biosciences, Inc. (-61.43%), greater than Nuvalent, Inc. (-28.83%), greater than Travere Therapeutics, Inc. (-102.43%), greater than Structure Therapeutics Inc. (-20.15%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Design Therapeutics, Inc. (-18.48%), greater than Werewolf Therapeutics, Inc. (-48.25%), greater than Ikena Oncology, Inc. (-42.81%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Blueprint Medicines Corporation (-85.25%), greater than IGM Biosciences, Inc. (-119.02%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Mineralys Therapeutics, Inc. (-42.61%),
Company | ROE | Market cap |
---|---|---|
-32.89% | $4.74B | |
-34.57% | $6.99B | |
-122.70% | $1.25B | |
-56.13% | $2.88B | |
-61.43% | $153.35M | |
-28.83% | $5.59B | |
-102.43% | $839.88M | |
-20.15% | $2.11B | |
-70.40% | $349.21M | |
-18.48% | $264.42M | |
-48.25% | $88.28M | |
-42.81% | $81.56M | |
-57.89% | $773.92M | |
-139.02% | $5.00B | |
-39.58% | $549.60M | |
-85.25% | $5.47B | |
-119.02% | $552.26M | |
-28.37% | $1.04B | |
-42.61% | $558.43M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cerevel Therapeutics Holdings, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cerevel Therapeutics Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Cerevel Therapeutics Holdings, Inc.'s ROE?
How is the ROE calculated for Cerevel Therapeutics Holdings, Inc. (CERE)?
What is the highest ROE for Cerevel Therapeutics Holdings, Inc. (CERE)?
What is the 3-year average ROE for Cerevel Therapeutics Holdings, Inc. (CERE)?
What is the 5-year average ROE for Cerevel Therapeutics Holdings, Inc. (CERE)?
How does the current ROE for Cerevel Therapeutics Holdings, Inc. (CERE) compare to its historical average?